Top-Rated StocksTop-RatedPositive News SentimentPositive NewsNASDAQ:IMCR Immunocore (IMCR) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free IMCR Stock Alerts $57.31 +1.49 (+2.67%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$56.25▼$57.9850-Day Range$53.37▼$71.6552-Week Range$42.21▼$76.98Volume302,166 shsAverage Volume484,334 shsMarket Capitalization$2.86 billionP/E RatioN/ADividend YieldN/APrice Target$80.55 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immunocore alerts: Email Address Immunocore MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside42.2% Upside$81.50 Price TargetShort InterestBearish9.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.73Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.54) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.43 out of 5 starsMedical Sector519th out of 910 stocksBiological Products, Except Diagnostic Industry80th out of 153 stocks 4.4 Analyst's Opinion Consensus RatingImmunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageImmunocore has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.49% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Immunocore has recently increased by 7.46%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMCR. Previous Next 3.2 News and Social Media Coverage News SentimentImmunocore has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Immunocore this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for IMCR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.10% of the stock of Immunocore is held by insiders.Percentage Held by Institutions84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunocore are expected to decrease in the coming year, from ($1.54) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -49.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -49.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 7.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHere’s how to start a “Weekend Side Hustle” from your sofaHere’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.Weekend after weekend! About Immunocore Stock (NASDAQ:IMCR)Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Read More IMCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMCR Stock News HeadlinesApril 16, 2024 | americanbankingnews.comImmunocore Holdings plc (NASDAQ:IMCR) Sees Significant Increase in Short InterestApril 13, 2024 | americanbankingnews.comImmunocore (NASDAQ:IMCR) Rating Reiterated by Needham & Company LLCApril 23, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 11, 2024 | markets.businessinsider.comImmunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)April 10, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - IMCRApril 5, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)April 5, 2024 | investing.comImmunocore executive sells shares worth over $280,000April 4, 2024 | globenewswire.comImmunocore to present at upcoming investor conferencesApril 23, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 16, 2024 | finance.yahoo.comIMCR Apr 2024 45.000 putMarch 16, 2024 | finance.yahoo.comIMCR Apr 2024 95.000 callMarch 11, 2024 | markets.businessinsider.comCastle Biosciences: A Strong Buy on Genomic Diagnostic Leadership and Market Growth PotentialMarch 6, 2024 | markets.businessinsider.comBuy Rating on Immunocore Holdings: Robust Financials and Promising Pipeline Signal GrowthMarch 5, 2024 | globenewswire.comImmunocore presented two posters at CROI 2024March 1, 2024 | seekingalpha.comImmunocore Holdings plc (IMCR) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | globenewswire.comImmunocore to present at upcoming investor conferencesFebruary 29, 2024 | markets.businessinsider.comKey Takeaways From Immunocore Hldgs Analyst RatingsFebruary 29, 2024 | finance.yahoo.comImmunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comImmunocore Holdings PLC (IMCR) Reports Strong Revenue Growth Amidst Expansion and Clinical ...February 28, 2024 | msn.comImmunocore GAAP EPS of -$0.40 misses by $0.13, revenue of $70.16M beats by $1.79MFebruary 28, 2024 | globenewswire.comImmunocore reports fourth quarter and full year 2023 financial results and provides a business updateFebruary 27, 2024 | msn.comImmunocore FY 2023 Earnings PreviewFebruary 24, 2024 | investing.comImmunocore Holdings Ltd (IMCR)February 22, 2024 | globenewswire.comImmunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trialFebruary 21, 2024 | finance.yahoo.comImmunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024February 21, 2024 | globenewswire.comImmunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024February 14, 2024 | finance.yahoo.comZacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma BiotechnologySee More Headlines Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IMCR CUSIPN/A CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees497Year FoundedN/APrice Target and Rating Average Stock Price Target$81.50 High Stock Price Target$92.00 Low Stock Price Target$63.00 Potential Upside/Downside+40.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,290,000.00 Net Margins-22.48% Pretax Margin-24.41% Return on Equity-15.78% Return on Assets-9.91% Debt Debt-to-Equity Ratio0.13 Current Ratio3.80 Quick Ratio3.77 Sales & Book Value Annual Sales$249.43 million Price / Sales11.45 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book7.72Miscellaneous Outstanding Shares49,820,000Free Float45,287,000Market Cap$2.86 billion OptionableOptionable Beta0.89 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Bahija Jallal Ph.D. (Age 63)CEO & Director Comp: $1.42MMr. Brian R. Di Donato M.B.A. (Age 57)CFO & Head of Strategy Mr. John Trainer M.B.A. (Age 50)SVP & Chief Operating Officer Mr. John Goll IIISVP, Finance & Chief Accounting OfficerMs. Annelise Vuidepot Ph.D.CTO and Head of Pipeline & Platform ResearchMr. Sean D. Buckley (Age 41)VP & Chief Information Officer Clayton RobertsonHead of Investor RelationsMs. Lily Margaret HepworthGeneral Counsel & Company SecretaryMs. Elizabeth Varki Jobes Esq. (Age 57)J.D., Chief Compliance Officer Mr. Sébastien DesprezHead of CommunicationsMore ExecutivesKey CompetitorsCG OncologyNASDAQ:CGONDenali TherapeuticsNASDAQ:DNLIArcellxNASDAQ:ACLXApogee TherapeuticsNASDAQ:APGEVericelNASDAQ:VCELView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 1,830 shares on 4/18/2024Ownership: 0.176%Hennion & Walsh Asset Management Inc.Bought 8,848 shares on 4/17/2024Ownership: 0.043%Wellington Management Group LLPBought 399,201 shares on 3/5/2024Ownership: 8.812%Great Point Partners LLCBought 2,083 shares on 2/15/2024Ownership: 0.599%Avidity Partners Management LPSold 48,000 shares on 2/14/2024Ownership: 0.613%View All Insider TransactionsView All Institutional Transactions IMCR Stock Analysis - Frequently Asked Questions Should I buy or sell Immunocore stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IMCR shares. View IMCR analyst ratings or view top-rated stocks. What is Immunocore's stock price target for 2024? 13 Wall Street research analysts have issued 12 month price objectives for Immunocore's shares. Their IMCR share price targets range from $63.00 to $92.00. On average, they predict the company's share price to reach $81.50 in the next year. This suggests a possible upside of 42.2% from the stock's current price. View analysts price targets for IMCR or view top-rated stocks among Wall Street analysts. How have IMCR shares performed in 2024? Immunocore's stock was trading at $68.32 at the start of the year. Since then, IMCR shares have decreased by 16.1% and is now trading at $57.31. View the best growth stocks for 2024 here. Are investors shorting Immunocore? Immunocore saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,610,000 shares, an increase of 7.5% from the March 15th total of 4,290,000 shares. Based on an average trading volume of 491,700 shares, the days-to-cover ratio is presently 9.4 days. Currently, 9.5% of the shares of the stock are short sold. View Immunocore's Short Interest. When is Immunocore's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our IMCR earnings forecast. How were Immunocore's earnings last quarter? Immunocore Holdings plc (NASDAQ:IMCR) issued its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.12. The company earned $70.16 million during the quarter, compared to the consensus estimate of $53.25 million. Immunocore had a negative net margin of 22.48% and a negative trailing twelve-month return on equity of 15.78%. Immunocore's quarterly revenue was up 22.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.63) earnings per share. What ETFs hold Immunocore's stock? ETFs with the largest weight of Immunocore (NASDAQ:IMCR) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Tema Oncology ETF (CANC), Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).BlackRock Future Health ETF (BMED). When did Immunocore IPO? Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO. Who are Immunocore's major shareholders? Immunocore's stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.18%) and Hennion & Walsh Asset Management Inc. (0.04%). View institutional ownership trends. How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMCR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
